Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy

• DOI: 10.1111/j.1445-5994.2005.00902.x
• Publication Date: 2005-08-15T10:40:29Z
• Authors: G. R. Fulcher; R. E. Gilbert; D. K. Yue
• Keywords: NPH insulin; Bedtime; Glycated hemoglobin; Insulin lispro; Glycated haemoglobin

Abstract Aim: To compare glycaemic control and symptomatic hypoglycaemia rates with glargine versus neutral protamine Hagedorn (NPH) in poorly controlled type 1 diabetes patients. Methods: Patients ( n = 125) received preprandial insulin lispro either 62) or NPH 63) at bedtime for 30 weeks a multicentre, randomized, single‐blind (a blinded investigator made titration decisions) study. Basal dosage was titrated to achieve fasting blood glucose (FBG) values <5.5 mmol/L. Results: Baseline characteristics were similar the two groups (mean duration 17.5 ± 10.1 years) except mean glycated haemoglobin (HbA 1c ), which lower group (9.2 1.1% vs 9.7 1.3%; P < 0.02). At end‐point, HbA 8.3 9.1% groups. Adjusted least‐squares (LSM) change from baseline –1.04 –0.51%, significant treatment benefit of 0.53% favour 0.01). Mean FBG (11.2 11.4 mmol/L). The means end‐point 7.9 9.0 LSM –3.46 –2.34 mmol/L, difference 1.12 mmol/L 0.05). There total numbers daytime mild, moderate severe episodes arms. However, significantly fewer nocturnal hypoglycaemic observed 0.04 Conclusion: Glargine is superior improving levels during intensive therapy patients diabetes, associated less hypoglycaemia. (Intern Med J 2005; 35: 536–542)